China enters CAR-T cell therapy era

A brief diagram of CAR-T therapy

The emerging individualized and living-cell-based genetic engineering chimeric antigen receptor T (CAR-T) therapy demonstrates great curative effects in some hematological tumor treatments, thus it is turning out to be a star immunotherapy method of the world.1 Recently, the China National Medical Products Administration (NMPA) approved launching applications of two CAR-T cell cancer products, Axicabtagene Ciloleucel (FKC876) and Relmacabtagene Autoleucel (Carteyva), which marked the beginning of the of CAR-T cell therapy era in China (Figure 1).

DOI:
https://doi.org/10.1016/j.xinn.2021.100197

Citation:
Cao X., Li W., Yu Y., et al. (2021). China enters CAR-T cell therapy era. The Innovation. 3(1),100197.